Edwards Lifesciences stock holds firm after Q2 beat
Published on 08/19/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences Corporation (US28176E1082) is holding a $52.47 billion market capitalization after the company said on July 23, 2026 that second-quarter earnings were $0.78 a share, above the $0.74 consensus, on revenue of $1.74 billion.
The same report showed revenue rising 13.6% from the prior year quarter, while management set Q3 2026 guidance at $0.71 to $0.77 a share and FY 2026 guidance at $2.95 to $3.05 a share.
Market value and earnings
Shares opened at $91.13 on August 18, 2026, with a 52-week range of $72.30 to $96.29 and a 50-day average of $88.90. The stock was up 0.35 percent in that session and closed at $91.13, keeping it close to the top of that range.
That setup gives investors a simple read: the market is still paying for a company that has delivered $0.78 in quarterly EPS, 13.6 percent revenue growth and a guidance range that points to another solid quarter.
What the latest quarter showed
In the July 23, 2026 quarter, Edwards Lifesciences posted net margin of 15.43 percent and return on equity of 15.68 percent. Those figures sit behind the premium valuation, with the latest P/E ratio at 52.37 and a PEG ratio of 2.30.
Consensus remains constructive. MarketBeat's coverage of the stock lists 17 Buy ratings and six Hold ratings, with an average target price of $100.27.
Business focus
Edwards Lifesciences is centered on structural heart disease and critical care monitoring, with TAVR, surgical tissue valves and related delivery systems as the core franchise. That product mix still matters because the quarter's 13.6 percent revenue growth shows demand remains intact across the platform.
Trading level to watch
With the shares at $91.13 on August 18, 2026, the stock sits $5.16 below the 52-week high of $96.29 and $18.83 above the 52-week low of $72.30. For now, the numbers point to a stock that has already re-rated, but not fully priced in the $100.27 average target.
Fact box
Company: Edwards Lifesciences Corporation
ISIN: US28176E1082
Ticker: EW
Exchange: NYSE
Price (as of August 18, 2026, 4:00 p.m. ET): $91.13 USD
Market cap: $52.47 billion
Sector / Industry: Health Care / Health Care Equipment
Index membership: S&P 500
